ELVN
Enliven Therapeutics, Inc.NASDAQHealthcare$38.83+2.75%ClosedMarket Cap: $2.32B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.80
P/S
0.00
EV/EBITDA
-19.49
DCF Value
$1.70
FCF Yield
-3.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-24.2%
ROA
-21.8%
ROIC
-26.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-34.3M | $-29.7M | $-0.45 | — |
| FY 2025 | $0.00 | -Infinity% | $-119.7M | $-103.7M | $-1.83 | — |
| Q3 2025 | $0.00 | NaN% | $-25.1M | $-20.1M | $-0.32 | — |
| Q2 2025 | $0.00 | NaN% | $-28.6M | $-25.3M | $-0.49 | — |
| Q1 2025 | $0.00 | NaN% | $-31.7M | $-28.5M | $-0.57 | — |
| Q4 2024 | $0.00 | NaN% | $-26.9M | $-23.2M | $-0.46 | — |
| FY 2024 | $0.00 | NaN% | $-104.6M | $-89.0M | $-1.89 | — |
| Q3 2024 | $0.00 | NaN% | $-27.1M | $-23.2M | $-0.48 | — |
| Q2 2024 | $0.00 | NaN% | $-24.6M | $-19.9M | $-0.41 | — |
| Q1 2024 | $0.00 | NaN% | $-26.0M | $-22.7M | $-0.54 | — |
| Q4 2023 | $0.00 | NaN% | $-22.7M | $-19.4M | $-0.47 | — |
| FY 2023 | $0.00 | NaN% | $-83.5M | $-71.6M | $-2.01 | — |